Physician profile
Jacques Halabi
NPI 1528544525
$2,418.82
in general payments reported to CMS, 2019-2025
13 companies · $861 in 2025
The $861 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $582 · 2024: $976 · 2025: $861.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,268 · Education: $151.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,267.83 |
| Education | $150.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $871.82 | 2023-2025 | Tremfya, Stelara |
| Abbvie INC. | $501.69 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $314.17 | 2023-2025 | Xifaxan, Plenvu, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $159.68 | 2023-2025 | Entyvio, Eohilia |
| Lilly USA, LLC | $123.27 | 2024-2025 | Omvoh |
| Mallinckrodt Hospital Products INC. | $106.37 | 2023-2025 | Terlivaz |
| Phathom Pharmaceuticals, INC. | $98.64 | 2024 | Voquezna |
| Pfizer INC. | $89.61 | 2024-2025 | |
| Qol Medical, LLC | $60.55 | 2025 | Sucraid |
| Organon LLC | $29.12 | 2025 | Hadlima, Renflexis |
| Merck Sharp & Dohme LLC | $23.41 | 2024 | Dificid |
| Ipsen Biopharmaceuticals, INC | $21.00 | 2024 | Iqirvo |
| Novo Nordisk INC | $19.49 | 2025 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacques Halabi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.